Mitomycin is active against refractory germ-cell tumors. A phase II study.
Mitomycin was used as single-agent therapy in seven male patients with nonseminomatous germ-cell tumors resistant to platinum analogues. The toxicity was high, especially hematological and pulmonary, in this heavily pretreated group. Mitomycin was active in this situation and one complete and one partial response of 18 and 20 weeks' duration, respectively, were seen.
Hoskins
P
P
Division of Medical Oncology, University of British Columbia, Vancouver, Canada.
Coppin
C M
CM
Murray
N
N
D000328:Adult; D002945:Cisplatin / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008168:Lung / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced
D008937:Mitomycins; D002945:Cisplatin